Dale Leffler, DO
Cardiovascular Disease · Holland, MINPI 1346463254
Payments from drug & device makers
Across 354 payments — averaging $55.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$6K
- Boston Scientific$1K
- Penumbra, Inc.$1K
- Biosense Webster, Inc.$501
- Shockwave Medical, Inc$469
- plus $3K from 32 others
What the payments were for
- Travel & lodging$9,71449%
- Food & beverage$10,05751%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 60 | $6,972 |
| Medtronic(2 entities) | 67 | $5,957 |
| Boston Scientific | 62 | $1,439 |
| Penumbra, Inc. | 3 | $1,407 |
| Biosense Webster, Inc. | 7 | $501 |
| Shockwave Medical, Inc | 16 | $469 |
| Johnson & Johnson | 20 | $360 |
| Novartis | 21 | $353 |
| Amgen | 6 | $261 |
| Philips North America LLC | 3 | $198 |
| E.r. Squibb & Sons, L.L.C. | 9 | $184 |
| Boehringer Ingelheim | 8 | $182 |
| AstraZeneca(2 entities) | 10 | $171 |
| Terumo Medical Corporation | 3 | $146 |
| Stryker | 7 | $145 |
| Abiomed | 5 | $86 |
| Scpharmaceuticals Inc. | 3 | $84 |
| Merck | 3 | $80 |
| Amarin Pharma, Inc. | 4 | $79 |
| Inari Medical, Inc. | 1 | $75 |
| Bayer | 5 | $72 |
| Pfizer | 3 | $70 |
| Angiodynamics, Inc. | 3 | $64 |
| Preventice Services, LLC | 1 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $48 |
| Actelion Pharmaceuticals US, Inc. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| GE HealthCare | 1 | $34 |
| Cardiovascular Systems Inc. | 3 | $33 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Cardinal Health 200 LLC | 1 | $23 |
| BD | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,946
- OMNILINK ELITE$1,838
- Indigo System$1,407
- PERCLOSE PROGLIDE$1,317
- Xience V coronary stent system$1,048
- SUPERA$790
- Carto 3$209
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$209
- COREVALVE EVOLUT R$171
- COROFLOW$122
- Micra$115
- LINQ II$112
- OPTIS$110
- (6575) Coronary Undivided$107
- ESPRIT$100
How this compares
$19,785 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 299 | $372,426 |
| EntrestoSacubitril/Valsartan | 70 | $88,063 |
| XareltoRivaroxaban | 59 | $61,324 |
| Repatha SureclickEvolocumab | 49 | $37,218 |
| JardianceEmpagliflozin | 32 | $32,194 |
| Metoprolol Succinate | 259 | $3,827 |
| Atorvastatin Calcium | 246 | $2,704 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 78 | $1,943 |
| Prasugrel Hcl | 41 | $1,910 |
| Losartan Potassium | 152 | $1,623 |
| ClopidogrelClopidogrel Bisulfate | 87 | $1,492 |
| Ezetimibe | 73 | $1,443 |
| Carvedilol | 138 | $1,326 |
| Ranolazine ErRanolazine | 22 | $1,194 |
| Flecainide Acetate | 34 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $372,426299 claims |
| NovartisEntresto | $353 | $88,06370 claims |
| Johnson & JohnsonXarelto | $360 | $61,32459 claims |
| Boehringer IngelheimJardiance | $182 | $32,19432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Holland
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.